Q-omics provides the consensus-scored NPM1P25 profile across patient tissues and cancer cell-line models. NPM1P25 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NPM1P25 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NPM1P25 RNA expression shows 16,768 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where NPM1P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPM1P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPM1P25 survival associations across molecular data types. NPM1P25 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPM1P25 RNA expression–survival associations across cancer types. High NPM1P25 expression shows favorable associations in BLCA, SKCM, KIRC, HNSC, CESC and ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for NPM1P25 RNA expression.
This table summarizes NPM1P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NPM1P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPM1P25 shows lower tumor expression in KIRC, HNSC, COAD, KIRP and LIHC and higher tumor expression in BRCA. The KIRC box plot shows higher NPM1P25 RNA expression in normal versus tumor tissue (log2 FC = −1.900, t-test p < 0.001).
This table shows molecular features associated with NPM1P25 in patient tissues and cancer cell lines. In patient samples, NPM1P25 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
